Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04647734 Completed - COVID-19, SARS-CoV2 Clinical Trials

The Protective Potential of Exercise Training on the Cardiopulmonary Morbidity After COVID-19

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

40 COVID-19 survivors that have been discharged from the hospital will be included in this investigator-blinded randomised study with a 12-week exercise intervention. Patients will be 1:1 block-randomised by sex to either a supervised high intensity interval-based exercise group or standard care (control group).

NCT ID: NCT04647682 Completed - COVID-19 Infection Clinical Trials

Physical Activity Program Implementation in Hospitalized Positive COVID-19 Older Adults

Cov-activity
Start date: January 5, 2021
Phase:
Study type: Observational

Our hypothesis was that physical activity program will be acceptable and may counteract physical and mental decline among older adults hospitalized in COVID-19 unit

NCT ID: NCT04647656 Completed - Covid19 Clinical Trials

Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome

HBOTpCOVID
Start date: December 14, 2020
Phase: N/A
Study type: Interventional

Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome

NCT ID: NCT04647604 Completed - COVID-19 Clinical Trials

Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -

Start date: June 23, 2020
Phase: Phase 2
Study type: Interventional

A study on patients who are hospitalized and tested positive for COVID-19 or have a typical CT image of COVID-19 infection, to establish if omega-3 Polyunsaturated Fatty Acid (PUFA) supplementation by intravenous route is a possible treatment option in COVID-19 with minimal risks to the patients.

NCT ID: NCT04646655 Completed - Covid19 Clinical Trials

Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19

EMOS-COVID
Start date: July 27, 2020
Phase: Phase 3
Study type: Interventional

SINGLE CENTER PHASE III INTERVENTIONAL RANDOMIZED CONTROLLED TRIAL comparing efficacy and safety of enoxaparin at prophylactic dose (standard treatment) and enoxaparin at therapeutic dose (OFF-LABEL treatment) in 300 COVID-19 infected patients with moderate-severe respiratory failure (PaO2/FiO2<250) and/or increased D-dimer levels enrolled in different Units (Infectious disease, Internal Medicine, Emergency Medicine, Pneumology) of Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco (ASST-FBF-SACCO).

NCT ID: NCT04646642 Completed - Covid19 Clinical Trials

Psychological Health, Coping Strategies and Preferences of Military COVID-19 Deployers

Start date: December 14, 2020
Phase:
Study type: Observational

The proposed research study aims to better understand COVID deployer needs. The study, informally referred to as Project COPE, asks David Grant U.S. Air Force Medical Center (DGMC) members who deployed in support of COVID-19 operations to complete a needs assessment questionnaire. The purpose of this study is to understand the stressful experiences of our COVID Theater Hospital (CTH) deployers, the typical coping strategies used and recommended preferences for support so that the investigators can provide the best evidence-based resources for post-deployment and to aid future CTH deployers.

NCT ID: NCT04646616 Completed - Covid19 Clinical Trials

CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.

CRISOL Contigo
Start date: January 15, 2021
Phase: N/A
Study type: Interventional

Latinos have been one of the racial/ethnic groups most impacted by the COVID-19 pandemic, and evidence of effective strategies to curb the pandemic, reduce disparities, and mitigate its impact is lacking and very urgent. The goal of this competitive revision is to expand an ongoing academic-community partnership to adapt, implement, and evaluate a multi-level intervention to mitigate the multi-dimensional toll of COVID19 among Latino immigrant communities in Philadelphia.

NCT ID: NCT04646239 Completed - Covid19 Clinical Trials

Biomarkers of Trained Immunity Following MMR Vaccination

Start date: December 17, 2020
Phase:
Study type: Observational

This is a substudy of NCT04333732. The goal of this sub-study is to identify and characterize biomarkers of trained immunity by measuring, in vitro, immune responses to heterologous products, especially viral associated products, in the MMR vaccinated compared placebo groups. All participants are randomly assigned to MMR or placebo injection at baseline, followed by SARS-CoV-2 specific vaccination. Blood is drawn around 60 to 90 days after the last SARS-CoV-2 specific vaccine injection.

NCT ID: NCT04646109 Completed - COVID-19 Clinical Trials

Ivermectin for Severe COVID-19 Management

Start date: May 11, 2020
Phase: Phase 3
Study type: Interventional

In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause side effects.

NCT ID: NCT04646044 Completed - Covid-19 Clinical Trials

A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

Start date: November 13, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in combination with standard of care (SOC) in adult patients with mild COVID-19 (coronavirus disease 2019). The trial will also define the recommended phase 2 dose (RP2D) of bempegaldesleukin in patients with mild COVID-19.